Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial-Reference-Cited by-同舟云学术

Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial

Published:2022-04 Issue:4 Volume:23 Page:540-552
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Kindler Hedy L,Novello Silvia,Bearz Alessandra,Ceresoli Giovanni L,Aerts Joachim G J V,Spicer James,Taylor Paul,Nackaerts Kristiaan,Greystoke Alastair,Jennens Ross,Calabrò Luana,Burgers Jacobus A,Santoro Armando,Cedrés Susana,Serwatowski Piotr,Ponce Santiago,Van Meerbeeck Jan P,Nowak Anna K,Blumenschein George,Siegel Jonathan M,Kasten Linda,Köchert Karl,Walter Annette O,Childs Barrett H,Elbi Cem,Hassan Raffit,Fennell Dean A

Publisher

Elsevier BV

Subject

Oncology

Reference26 articles.

1. Emerging treatments for malignant pleural mesothelioma: where are we heading?;Cantini;Front Oncol,2020

2. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma;Jassem;J Clin Oncol,2008

3. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial;Fennell;Lancet Oncol,2021

4. MS13·06 role of second line chemotherapy and new target treatment in recurrent mesothelioma;Novello;J Thorac Oncol,2019

5. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline;Kindler;J Clin Oncol,2018

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SMAC mimetics overcome apoptotic resistance in ovarian cancer through MSLN-TNF alpha axis;2024-01-26

2. Diffuse Pleural Mesothelioma: Advances in Molecular Pathogenesis, Diagnosis, and Treatment;Annual Review of Pathology: Mechanisms of Disease;2024-01-24

3. Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression;Journal of Gynecologic Oncology;2024

4. Current State-of-the-Art Therapy for Malignant Pleural Mesothelioma and Future Options Centered on Immunotherapy;Cancers;2023-12-10

5. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review;Critical Reviews in Oncology/Hematology;2023-12